DiscGenics, Inc. (DiscGenics) announces that the company has been selected as a Global Innovations Partner by Cavendish Global. Cavendish Global provides family offices, foundations and impact investors with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. The group conducted a global search of research institutions and private sector companies in order to identify organizations that meet the required standard of excellence. This selection highlights that the DiscGenics strong leadership, scientific innovation, and business acumen positions them to increase quality of life for patients and to reduce costs to the healthcare system by treating degenerative disc disease with their novel adult progenitor cells, Discogenic Cells.
About DiscGenics, Inc.
DiscGenics is a privately funded biotechnology company developing advanced spinal stem cell therapeutics to treat patients with diseases of the intervertebral disc. News and other information are available at: http://www.DiscGenics.com.
Bob Wynalek, Chief Operating and Commercialization Officer